Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)
2014년 11월 12일 업데이트: Novartis Pharmaceuticals
A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD
This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.
연구 개요
상태
완전한
연구 유형
중재적
등록 (실제)
449
단계
- 3단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Athens, 그리스, 11527
- Novartis Investigative Site
-
-
GR
-
Athens, GR, 그리스, 115 27
- Novartis Investigative Site
-
Athens, GR, 그리스, 106 76
- Novartis Investigative Site
-
Thessaloniki, GR, 그리스, 564 03
- Novartis Investigative Site
-
-
-
-
-
Moscow, 러시아 연방, 125315
- Novartis Investigative Site
-
N.Novgorod, 러시아 연방, 603126
- Novartis Investigative Site
-
Nizhny Novgorod, 러시아 연방, 603018
- Novartis Investigative Site
-
Saratov, 러시아 연방, 410012
- Novartis Investigative Site
-
-
-
-
-
Brussel, 벨기에, 1090
- Novartis Investigative Site
-
Bruxelles, 벨기에, 1070
- Novartis Investigative Site
-
Genk, 벨기에, 3600
- Novartis Investigative Site
-
Gilly, 벨기에, 6060
- Novartis Investigative Site
-
Gosselies, 벨기에, 6041
- Novartis Investigative Site
-
Hasselt, 벨기에, 3500
- Novartis Investigative Site
-
Herentals, 벨기에, 2200
- Novartis Investigative Site
-
Jambes, 벨기에, 5100
- Novartis Investigative Site
-
Liège, 벨기에, 4000
- Novartis Investigative Site
-
Luxembourg, 벨기에, 1210
- Novartis Investigative Site
-
Malmedy/Bellevaux-Ligneuville, 벨기에, 4960
- Novartis Investigative Site
-
Montigny-le-tilleul, 벨기에, 6110
- Novartis Investigative Site
-
Turnhout, 벨기에, 2300
- Novartis Investigative Site
-
Yvoir, 벨기에, 5530
- Novartis Investigative Site
-
-
-
-
-
Pleven, 불가리아, 5800
- Novartis Investigative Site
-
Plovdiv, 불가리아, 4002
- Novartis Investigative Site
-
Ruse, 불가리아, 7002
- Novartis Investigative Site
-
Sofia, 불가리아, 1431
- Novartis Investigative Site
-
Sofia, 불가리아, 1606
- Novartis Investigative Site
-
Sofia, 불가리아, 1000
- Novartis Investigative Site
-
Stara Zagora, 불가리아, 6000
- Novartis Investigative Site
-
Varna, 불가리아, 9010
- Novartis Investigative Site
-
-
-
-
-
Barcelona, 스페인, 08025
- Novartis Investigative Site
-
-
Andalucia
-
Malaga, Andalucia, 스페인, 29010
- Novartis Investigative Site
-
-
Asturias
-
Gijon, Asturias, 스페인, 33290
- Novartis Investigative Site
-
-
Cantabria
-
Torrelavega, Cantabria, 스페인, 39300
- Novartis Investigative Site
-
-
Castilla la Mancha
-
Illescas, Castilla la Mancha, 스페인, 45200
- Novartis Investigative Site
-
-
Castilla y Leon
-
Ponferrada, Castilla y Leon, 스페인, 24400
- Novartis Investigative Site
-
-
Cataluña
-
Centelles, Cataluña, 스페인, 08540
- Novartis Investigative Site
-
Salt, Cataluña, 스페인, 17190
- Novartis Investigative Site
-
Sant Boi de Llobregat, Cataluña, 스페인, 08830
- Novartis Investigative Site
-
Viladecans, Cataluña, 스페인
- Novartis Investigative Site
-
-
Extremadura
-
Mérida, Extremadura, 스페인, 06800
- Novartis Investigative Site
-
-
-
-
-
Bratislava, 슬로바키아, 826 06
- Novartis Investigative Site
-
Kosice, 슬로바키아, 040 01
- Novartis Investigative Site
-
Kralovsky Chlmec, 슬로바키아, 077 01
- Novartis Investigative Site
-
-
Slovak Republic
-
Bardejov, Slovak Republic, 슬로바키아, 085 01
- Novartis Investigative Site
-
Bojnice, Slovak Republic, 슬로바키아, 972 01
- Novartis Investigative Site
-
Liptovsky Hradok, Slovak Republic, 슬로바키아, 033 01
- Novartis Investigative Site
-
-
Slovensko
-
Námestovo, Slovensko, 슬로바키아, 02901
- Novartis Investigative Site
-
-
-
-
Cork
-
Wilton, Cork, 아일랜드
- Novartis Investigative Site
-
-
-
-
-
Bath, 영국, BA1 2SR
- Novartis Investigative Site
-
Bexhill-on-Sea, 영국, TN40 1JJ
- Novartis Investigative Site
-
Blackpool, 영국, FY3 7EN
- Novartis Investigative Site
-
Bradford, 영국, BD9 6RJ
- Novartis Investigative Site
-
Cambridge, 영국, CB7 5JD
- Novartis Investigative Site
-
Chesterfield, 영국, S40 4AA
- Novartis Investigative Site
-
Huntingdon, 영국, PE29 6NT
- Novartis Investigative Site
-
Manchester, 영국, M20 2RN
- Novartis Investigative Site
-
Newcastle-upon-Tyne, 영국, NE7 7DN
- Novartis Investigative Site
-
Newton Aycliffe, 영국, DL5 4SE
- Novartis Investigative Site
-
Reading, 영국, RG7 3SQ
- Novartis Investigative Site
-
Southbourne, 영국
- Novartis Investigative Site
-
Telford, 영국, TF1 6TF
- Novartis Investigative Site
-
Watford, 영국, WD25 0EA
- Novartis Investigative Site
-
Wiltshire, 영국, SN15 2SB
- Novartis Investigative Site
-
-
County Durham
-
Burnhope, County Durham, 영국, DH7 0BD
- Novartis Investigative Site
-
-
Suffolk
-
Alderton, Suffolk, 영국, IP12 3DA
- Novartis Investigative Site
-
-
Warwickshire
-
Atherstone, Warwickshire, 영국, CV9 1EU
- Novartis Investigative Site
-
Leamington Spa, Warwickshire, 영국, CV32 4RA
- Novartis Investigative Site
-
-
Yorkshire
-
Strensall, Yorkshire, 영국, YO32 5UA
- Novartis Investigative Site
-
-
-
-
-
Ankara, 칠면조, 06490
- Novartis Investigative Site
-
Istanbul, 칠면조, 34854
- Novartis Investigative Site
-
Istanbul, 칠면조
- Novartis Investigative Site
-
Kocaeli, 칠면조, 41380
- Novartis Investigative Site
-
Mersin, 칠면조, 33079
- Novartis Investigative Site
-
Yenisehir/Izmir, 칠면조, 35110
- Novartis Investigative Site
-
-
-
-
-
Budapest, 헝가리, 1121
- Novartis Investigative Site
-
Budapest, 헝가리, 1046
- Novartis Investigative Site
-
Deszk, 헝가리, 6772
- Novartis Investigative Site
-
Erd, 헝가리, H-2030
- Novartis Investigative Site
-
Godollo, 헝가리, 2100
- Novartis Investigative Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
40년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Patients with moderate to severe stable Chronic Obstructive Lung Disease (COPD) Stage II or Stage III according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
- Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30 % and/or <80 % of the predicted normal, and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) < 0.70 at screening.
- Current or ex-smokers who have a smoking history of at least 10 pack years
- Symptomatic patients according to daily diary data.
Exclusion Criteria:
- Pregnant or nursing (lactating) women.
- Women of child-bearing potential unless using adequate contraception.
- Patients with Type I or uncontrolled Type II diabetes.
- Patients with a history of long time interval between start of Q wave and end of T wave in the heart's electrical cycle (QT) syndrome or whose QT corrected for heart rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged
- Patients with paroxysmal (e.g. intermittent) atrial fibrillation
- Patients who have a clinically significant electrocardiogram (ECG) or laboratory abnormality at screening (Visit 2)
Other protocol-defined inclusion/exclusion criteria may apply.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: NVA237 + indacaterol
|
NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
다른 이름들:
|
|
위약 비교기: Placebo to NVA237 + indacaterol
|
Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Trough Forced Expiratory Volume at 1 Second (FEV1)
기간: 12 weeks
|
Centralized spirometry according to internationally accepted standards was used.
The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect.
If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward.
These measurements had to have been taken before the next dose of study medication.
FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
|
12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose
기간: 12 weeks
|
Centralized spirometry was used according to internationally accepted standards was used.
The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time.
Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated).
Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1.
FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
|
12 weeks
|
|
Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks
기간: 12 weeks
|
Centralized spirometry was used according to internationally accepted standards was used.
Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing.
The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect.
If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated.
FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
|
12 weeks
|
|
FEV1 at Individual Time-points
기간: Day 1, Day 29, Day 57 and Days 84/85
|
Centralized spirometry according to internationally accepted standards was used.
FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit.
The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect.
FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.
|
Day 1, Day 29, Day 57 and Days 84/85
|
|
Forced Vital Capacity (FVC) at Individual Time-points
기간: Day 1, Day 29, Day 57 and Days 84/85
|
FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit.
The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect.
FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.
|
Day 1, Day 29, Day 57 and Days 84/85
|
|
Inspiratory Capacity (IC) at Individual Time-points
기간: Day 1, Days 84/85
|
Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit.
The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect.
IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.
|
Day 1, Days 84/85
|
|
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
기간: Baseline, 12 weeks
|
The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening.
The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient.
If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.
|
Baseline, 12 weeks
|
|
Transitional Dyspnea Index (TDI) Focal Score
기간: baseline, 12 weeks
|
Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI).
Analysis was done via mixed model.
The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort.
BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity.
TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration.
A TDI focal score of 1 is considered a minimal clinically important difference.
|
baseline, 12 weeks
|
|
Change From Baseline in Mean Daily Total and Individual Symptom Scores
기간: Baseline, 12 weeks
|
The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect.
Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied.
For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom.
The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).
|
Baseline, 12 weeks
|
|
Number of Participants With Adverse Events and Serious Adverse Events
기간: 12 weeks
|
All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.
|
12 weeks
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2012년 5월 1일
기본 완료 (실제)
2013년 1월 1일
연구 완료 (실제)
2013년 1월 1일
연구 등록 날짜
최초 제출
2012년 5월 21일
QC 기준을 충족하는 최초 제출
2012년 5월 21일
처음 게시됨 (추정)
2012년 5월 23일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2014년 11월 14일
QC 기준을 충족하는 마지막 업데이트 제출
2014년 11월 12일
마지막으로 확인됨
2014년 11월 1일
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- CNVA237A2316
- 2011-005673-23 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
NVA237 50 µg and indacaterol 150 µg에 대한 임상 시험
-
Novartis Pharmaceuticals완전한
-
Orion Corporation, Orion Pharma완전한
-
Mundipharma Research Limited완전한
-
Makassed General Hospital모병
-
Institut National de la Santé Et de la Recherche...EVI Industries, Inc.; BPRC; Recherche Clinique Paris Descartes Necker Cochin Sainte Anne; Centre...완전한